吉西他滨联合多西紫杉醇治疗晚期非小细胞肺癌41例

目的观察吉西他滨联合多西紫杉醇与吉西他滨联合顺铂治疗晚期非小细胞肺癌（NSCLC）的临床疗效及不良反应。方法82例经病理或细胞学证实的晚期NSCLC的患者随机分为2组，GT组4l例（吉西他滨联合多西紫杉醇）与GP组41例（吉西他滨联合顺铂）。吉西他滨1g／m2，d1，8静脉滴注30min；多西紫衫醇75mg／m2，d1静脉滴注1h；顺铂35mg／m2，d，1-3；21d为1个周期，至少治疗2个周期。按WHO疗效分级及抗癌药物毒性反应分度标准进行评价。结果GT组总有效率为51．22％（CR＋PR），GP组总有效率为46．63％，两组比较无统计学差异（P〉0．05）。GT组Ⅲ～Ⅳ度白细胞减少、Ⅲ～Ⅳ度血小板下降、及消化道反应均明显低于GP组（P〈0．05）。结论GT与GP两种方案对晚期NSCLC的疗效都较理想，但GT方案较后者不良反应更低，是可以替代铂类药物的有效方案。

Objective to evaluate the efficacy and toxicity by gemcitabine plus decetaxel （GT） and gemcitabine plus cisplatin（GP） in teatment of NSCLC.Methods 82 NSCLC patients were randomized into GP and GT group ,and were evaluated in the efficacy and toxicity after 2 courses of treatment.Results There is no statistical significance in the response rates of GT and GP group （P〉 0.05）.The main side-effects were including vomiting,disgusting,Decreasing of the number of white blood cells and platelets. There were statistical significance（P〈0.05）.Conclusions The effect by GT and GP plan for NSCLC are both good,but the toxicity of GT are more loweroThe GT plan is worth promoting the application in clinic.